BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory


Biognosys logo


Biognosys believe that the decoding of the proteome will impact the life sciences more than the genome revolution a decade ago, and they strive to be the company that enables the routine analysis of proteomes in each research and clinical laboratory worldwide.

Biognosys offers a unique next-generation solution for precise quantification of large proteomes in biological samples. Their technology provides unprecedented DEBTh and quality of protein expression data for more effective biomarker and drug-target discovery and validation.
Biognosys is a spin-off from the leading proteomics lab of Prof. Ruedi Aebersold, ETH Zurich.

Posts Mentioning This Company

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.